IMCD Stock Analysis: IMCD | AS
Specialty Chemicals | AS, Netherlands | Market Cap: 5.699m EUR | 12M Return: 8.1% | NL0010801007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.9M
EPS Trend: -2.4%
Rev. Trend: 95.3%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IMCD N.V. is a global specialty chemicals and ingredients distributor headquartered in Rotterdam, the Netherlands, founded in 1995. The company markets and sells a broad portfolio of chemical inputs to customers across Europe, the Middle East, Africa, the Americas, and Asia-Pacific, serving diverse end markets including plastics, personal care and cosmetics, coatings, food and nutrition, home care and industrial cleaning, lubricants, and oil and gas.
Its product range spans plastic additives (such as pigments, plasticizers, flame retardants, and thermoplastic elastomers), personal care ingredients (including surfactants, emollients, UV filters, and fragrances), home care and cleaning chemicals (such as enzymes, biocides, builders, and surfactants), and oilfield and lubricant specialties (including base oils, fuel additives, and solvents).
IMCD operates within the Trading Companies & Distributors sub-industry, where value is created through technical sales support, formulation expertise, and supply chain management rather than chemical manufacturing. Distributors in this segment typically function as intermediaries between chemical producers and industrial customers, earning margins on the spread between purchase and sale prices while providing logistics, market knowledge, and regulatory support to principals and clients.
- M&A fueled revenue growth accelerates across emerging markets
- European industrial slowdown pressures specialty chemicals volumes
- Gross margins expand as product mix shifts toward higher value specialties
| Net Income: 230.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.58 > 1.0 |
| NWC/Revenue: 10.99% < 20% (prev 16.50%; Δ -5.51% < -1%) |
| CFO/TA 0.08 > 3% & CFO 384.0m > Net Income 230.2m |
| Net Debt (1.66b) to EBITDA (532.2m): 3.13 < 3 |
| Current Ratio: 1.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.0m) vs 12m ago 3.68% < -2% |
| Gross Margin: 9.75% > 18% (prev 18.72%; Δ -8.97% > 0.5%) |
| Asset Turnover: 103.3% > 50% (prev 104.4%; Δ -1.09% > 0%) |
| Interest Coverage Ratio: 4.64 > 6 (EBIT TTM 385.4m / Interest Expense TTM 83.1m) |
| A: 0.11 (Total Current Assets 2.11b - Total Current Liabilities 1.56b) / Total Assets 4.95b |
| B: 0.21 (Retained Earnings 1.04b / Total Assets 4.95b) |
| C: 0.08 (EBIT TTM 385.4m / Avg Total Assets 4.79b) |
| D: 0.75 (Book Value of Equity 2.12b / Total Liabilities 2.82b) |
| Altman-Z'' = 2.74 = A |
| DSRI: 1.15 (Receivables 1.08b/916.4m, Revenue 4.94b/4.83b) |
| GMI: 1.92 (GM 18.72% / 9.75%) |
| AQI: 0.96 (AQ_t 0.54 / AQ_t-1 0.57) |
| SGI: 1.02 (Revenue 4.94b / 4.83b) |
| TATA: -0.03 (NI 230.2m - CFO 384.0m) / TA 4.95b) |
| Beneish M = -2.08 (Cap -4..+1) = BB |
As of October 07, 2026, the stock is trading at EUR 98.16 with a total of 157,849 shares traded. Over the past week, the price has changed by +2.06%, over one month by +1.47%, over three months by +15.37% and over the past year by +8.13%.
Current recommended Stop Loss: 95.40 (which is 2.8% or 1.2 ATR below the current price).
IMCD has no consensus analysts rating.
P/E Trailing = 24.8123
P/E Forward = 13.9082
P/S = 1.1468
P/B = 2.6077
Revenue TTM = 4.94b EUR
EBIT TTM = 385.4m EUR
EBITDA TTM = 532.2m EUR
Long Term Debt = 1.29b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 734.0m EUR (from shortTermDebt, last quarter)
Debt = 1.91b EUR (from shortLongTermDebtTotal, last quarter) + Leases 104.2m
Net Debt = 1.66b EUR (calculated: Debt 1.91b - CCE 248.7m)
Enterprise Value = 7.36b EUR (5.70b + Debt 1.91b - CCE 248.7m)
Interest Coverage Ratio = 4.64 (Ebit TTM 385.4m / Interest Expense TTM 83.1m)
EV/FCF = 19.88x (Enterprise Value 7.36b / FCF TTM 370.4m)
FCF Yield = 5.03% (FCF TTM 370.4m / Enterprise Value 7.36b)
FCF Margin = 7.49% (FCF TTM 370.4m / Revenue TTM 4.94b)
Net Margin = 4.66% (Net Income TTM 230.2m / Revenue TTM 4.94b)
Gross Margin = 9.75% ((Revenue TTM 4.94b - Cost of Revenue TTM 4.46b) / Revenue TTM)
Gross Margin QoQ = 10.61% (prev 8.77%)
Tobins Q-Ratio = 1.49 (Enterprise Value 7.36b / Total Assets 4.95b)
Interest Expense / Debt = 4.34% (Interest Expense 83.1m / Debt 1.91b)
Taxrate = 26.49% (82.9m / 313.1m)
NOPAT = 283.4m (EBIT 385.4m * (1 - 26.49%))
Current Ratio = 1.35 (Total Current Assets 2.11b / Total Current Liabilities 1.56b)
Debt / Equity = 0.90 (Debt 1.91b / totalStockholderEquity, last quarter 2.12b)
Debt / EBITDA = 3.13 (Net Debt 1.66b / EBITDA 532.2m)
Debt / FCF = 4.49 (Net Debt 1.66b / FCF TTM 370.4m)
Total Stockholder Equity = 2.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.81% (Net Income 230.2m / Total Assets 4.95b)
RoE = 11.02% (Net Income TTM 230.2m / Total Stockholder Equity 2.09b)
RoCE = 11.41% (EBIT 385.4m / Capital Employed (Equity 2.09b + L.T.Debt 1.29b))
RoIC = 7.33% (NOPAT 283.4m / Invested Capital 3.87b)
WACC = 6.41% (E(5.70b)/V(7.61b) * Re(7.49%) + D(1.91b)/V(7.61b) * Rd(4.34%) * (1-Tc(0.26)))
Discount Rate = 7.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 83.47 | Cagr: 1.47%
[DCF] Terminal Value 77.97% ; FCFF base≈313.1m ; Y1≈358.9m ; Y5≈528.2m
[DCF] Fair Price = 106.4 (EV 7.95b - Net Debt 1.66b = Equity 6.28b / Shares 59.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -2.45 | EPS CAGR: -0.19% | SUE: N/A | # QB: 0
Revenue Correlation: 95.28 | Revenue CAGR: 4.14% | SUE: 1.88 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=6.05 | Chg30d=+0.58% | Revisions=+46% | GrowthEPS=+16.5% | GrowthRev=+8.3%
EPS next Year (2027-12-31): EPS=6.53 | Chg30d=+0.92% | Revisions=+62% | GrowthEPS=+8.0% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: +61% (up=17, down=3)